|
gptkbp:instanceOf
|
gptkb:drug
radiopharmaceutical
|
|
gptkbp:activeIngredient
|
lutetium (177Lu) oxodotreotide
|
|
gptkbp:administeredBy
|
amino acid solution (to protect kidneys)
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
V10XX04
|
|
gptkbp:CASNumber
|
1525905-02-2
|
|
gptkbp:chemicalFormula
|
C65H87ClN14O19S2Lu
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:halfLife
|
about 6.7 days (for 177Lu)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lutathera
|
|
gptkbp:indication
|
unresectable or metastatic, well-differentiated, somatostatin receptor-positive GEP-NETs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Advanced_Accelerator_Applications
|
|
gptkbp:mechanismOfAction
|
binds to somatostatin receptors
delivers targeted radiation
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:DB13963
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
fatigue
thrombocytopenia
leukopenia
increased liver enzymes
renal toxicity
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:UNII
|
8Y7R8LJ8T6
|
|
gptkbp:usedFor
|
treatment of gastroenteropancreatic neuroendocrine tumors
|
|
gptkbp:bfsParent
|
gptkb:Advanced_Accelerator_Applications
|
|
gptkbp:bfsLayer
|
6
|